Michele Rhee
Vice President, Patient Experience, Patient Advocacy & Early Access Savara Pharmaceuticals
Michele Rhee is Vice President of Patient Experience at Savara Inc. She has two decades of experience leading patient advocacy and expanded access programs across biopharmaceutical and nonprofit industries. Michele was previously Vice President of Patient Affairs and Advocacy at X4 Pharmaceuticals, Head of Patient Affairs at Enzyvant, Global and R&D Patient Advocacy Lead at Takeda Oncology, Head of Patient Advocacy at bluebird bio, and Director of Strategic Initiatives and Program Initiatives at the National Brain Tumor Society. Michele received her MPH from Yale School of Public Health and MBA from Yale School of Management.
Seminars
Thursday 26th March 2026
Roundtable: Rare & Ultra-Rare Diseases: Designing Programs for Maximum Patient Impact
1:30 pm
- How are organisations currently navigating corporate pressures while maintaining ethical and equitable access in rare and ultra-rare disease programs?
- What are the key challenges sponsors face when deciding between single-patient access and cohort programs in today’s regulatory environment?
- What practical program design or operational approaches have been most effective in ensuring meaningful patient access in rare and ultra-rare diseases?
